Citadel Advisors’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-16,800
| Closed | -$251K | – | 16248 |
|
|
2022
Q4 | $251K | Sell |
16,800
-34,200
| -67% | -$474K | ﹤0.01% | 9686 |
|
|
2022
Q3 | $420K | Sell |
51,000
-38,600
| -43% | -$296K | ﹤0.01% | 8852 |
|
|
2022
Q2 | $588K | Sell |
89,600
-17,300
| -16% | -$83.8K | ﹤0.01% | 8282 |
|
|
2022
Q1 | $598K | Buy |
106,900
+5,220
| +5% | +$21.5K | ﹤0.01% | 8970 |
|
|
2021
Q4 | $477K | Buy |
101,680
+28,900
| +40% | +$179K | ﹤0.01% | 9815 |
|
|
2021
Q3 | $450K | Sell |
72,780
-11,120
| -13% | -$66.5K | ﹤0.01% | 10136 |
|
|
2021
Q2 | $553K | Sell |
83,900
-59,100
| -41% | -$407K | ﹤0.01% | 9845 |
|
|
2021
Q1 | $1.05M | Buy |
143,000
+72,300
| +102% | +$624K | ﹤0.01% | 7998 |
|
|
2020
Q4 | $408K | Sell |
70,700
-11,700
| -14% | -$67K | ﹤0.01% | 8527 |
|
|
2020
Q3 | $489K | Buy |
82,400
+5,300
| +7% | +$26.2K | ﹤0.01% | 7344 |
|
|
2020
Q2 | $397K | Buy |
77,100
+54,900
| +247% | +$347K | ﹤0.01% | 7456 |
|
|
2020
Q1 | $80K | Sell |
22,200
-6,900
| -24% | -$34.2K | ﹤0.01% | 8789 |
|
|
2019
Q4 | $182K | Buy |
29,100
+440
| +2% | +$3.24K | ﹤0.01% | 8258 |
|
|
2019
Q3 | $242K | Sell |
28,660
-4,160
| -13% | -$31K | ﹤0.01% | 7889 |
|
|
2019
Q2 | $221K | Buy |
32,820
+6,450
| +24% | +$55.3K | ﹤0.01% | 8051 |
|
|
2019
Q1 | $216K | Sell |
26,370
-13,750
| -34% | -$142K | ﹤0.01% | 8110 |
|
|
2018
Q4 | $642K | Buy |
40,120
+22,540
| +128% | +$496K | ﹤0.01% | 6012 |
|
|
2018
Q3 | $582K | Buy |
17,580
+6,370
| +57% | +$164K | ﹤0.01% | 6457 |
|
|
2018
Q2 | $253K | Buy |
11,210
+6,010
| +116% | +$143K | ﹤0.01% | 7509 |
|
|
2018
Q1 | $151K | Buy |
5,200
+1,810
| +53% | +$53K | ﹤0.01% | 7533 |
|
|
2017
Q4 | $95K | Sell |
3,390
-2,410
| -42% | -$74.8K | ﹤0.01% | 7454 |
|
|
2017
Q3 | $212K | Buy |
+5,800
| New | +$179K | ﹤0.01% | 6613 |
|
|
2017
Q1 | – | Sell |
-1,070
| Closed | -$6K | – | 8309 |
|
|
2016
Q4 | $6K | Sell |
1,070
-790
| -42% | -$5.27K | ﹤0.01% | 7164 |
|
|
2016
Q3 | $17K | Buy |
1,860
+850
| +84% | +$8K | ﹤0.01% | 7098 |
|
|
2016
Q2 | $10K | Sell |
1,010
-390
| -28% | -$3.76K | ﹤0.01% | 6726 |
|
|
2016
Q1 | $13K | Sell |
1,400
-630
| -31% | -$6.24K | ﹤0.01% | 6572 |
|
|
2015
Q4 | $26K | Sell |
2,030
-3,500
| -63% | -$41.6K | ﹤0.01% | 7769 |
|
|
2015
Q3 | $67K | Buy |
5,530
+5,200
| +1,576% | +$75.1K | ﹤0.01% | 7346 |
|
|
2015
Q2 | $6K | Buy |
+330
| New | +$5.94K | ﹤0.01% | 8523 |
|
Citadel Advisors's AVEO Position: Q1 2023 in Review
Citadel Advisors sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 315,477 shares — an estimated $4.72M sold.
Citadel Advisors first reported a position in AVEO in Q2 2013 and held it in 25 quarters. The position peaked at $4.72M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- Citadel Advisors reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 315,477 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $4.72M.
- Citadel Advisors first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 25 quarters.
- Citadel Advisors's AVEO Pharmaceuticals, Inc. position peaked at $4.72M in Q4 2022.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.